Production and binding analyses of a humanised scFv against a cryptic epitope on tumour-associated fibronectin

Protein Expression and Purification

Volumn 88, Issue 1, 2013, Pages 157-163

  Johdi, Nor Adzimah ^a,b   Harman, Ruth ^a   Sanjuan, Irene ^a,c   Kousparou, Christina ^a,d   Courtenay Luck, Nigel ^a   Deonarain, Mahendra P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^c London Research Institute   (United Kingdom)

^d Bank of Cyprus Group Oncology Centre   (Cyprus)

Author keywords

Binding; EDB fibronectin; Flow cytometry; Humanized; Single chain Fv; Surface plasmon resonance

Indexed keywords

EPITOPE; FIBRONECTIN; IMMUNOGLOBULIN FRAGMENT; ISOPROTEIN; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BIOSYNTHESIS; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; MOLECULAR CLONING; MOUSE; SURFACE PLASMON RESONANCE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CLONING, MOLECULAR; EPITOPES; FIBRONECTINS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MICE; PROTEIN ISOFORMS; SINGLE-CHAIN ANTIBODIES; SURFACE PLASMON RESONANCE;

EID: 84873875792     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2012.12.002     Document Type: Article

References (37)

1. M.P. Deonarain, M. P. Recombinant antibodies for cancer therapy. Expert Opin Biol Ther. 8 (2008) 1123-41.
2. G. Walsh Biopharmaceutical benchmarks Nat. Biotechnol. 28 2010 2010 917 924
3. A.M. Scott, J.D. Wolchok, and L.J. Old Antibody therapy of cancer Nat. Rev. Cancer 12 2012 278 287
4. T. Yokota, D. Milenic, M. Whitlow, and J. Schlom Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms Cancer Res. 52 1992 3402 3408
5. L.J. Holt, C. Herring, L.S. Jespers, B.P. Woolven, and I.M. Tomlinson Domain antibodies: proteins for therapy Trends Biotechnol. 21 2003 484 490 (Pubitemid 37324200)
6. D. Berndorff, S. Borkowski, D. Moosmayer, F. Viti, B. Müller-Tiemann, S. Sieger, M. Friebe, C.S. Hilger, L. Zardi, D. Neri, and L.M. Dinkelborg Imaging of tumor angiogenesis using 99mTc- labeled human recombinant anti-ED-B fibronectin antibody fragments J. Nucl. Med. 47 2006 1707 1716 (Pubitemid 47545038)
7. A.D. Roth, C. Drummond, F. Conrad, M.E. Hayes, D.B. Kirpotin, C.C. Benz, J.D. Marks, and B. Liu Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells Mol. Cancer Ther. 6 2007 2737 2746 (Pubitemid 350058154)
8. M. Bhatti, G. Yahioglu, L.R. Milgrom, M. Garcia-Maya, K.A. Chester, and M.P. Deonarain Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments Int. J. Cancer 122 2008 1155 1163
9. M. Steiner, and D. Neri Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends Clin. Cancer Res. 17 2011 6406 6416
10. H.J. Burstein Bevacizumab for Advanced Breast Cancer: All Tied Up With a RIBBON? J. Clin. Oncol. 29 2011 1232 1235
11. D. Fukumura, and R.K. Jain Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize J. Cell Biochem. 101 2007 937 949 (Pubitemid 47040874)
12. M. Kaspar, L. Zardi, and D. Neri Fibronectin as target for tumor therapy Int. J. Cancer 118 2006 1331 1339
13. S.I. Rudnick, J. Lou, C.C. Shaller, Y. Tang, A.J. Klein-Szanto, L.M. Weiner, J.D. Marks, and G.P. Adams Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors Cancer Res. 71 2001 2250 2259
14. E. Van Obberghen-Schilling, R.P. Tucker, F. Saupe, I. Gasser, B. Cseh, and G. Orend Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth Int. J. Dev. Biol. 55 2011 511 525
15. E.S. White, F.E. Baralle, and A.F. Muro New insights into form and function of fibronectin splice variants J. Pathol. 216 2008 1 14
16. P. Castellani, A. Siri, C. Rosellini, E. Infusini, L. Borsi, and L. Zardi Transformed human cells release different fibronectin variants than do normal cells J. Cell Biol. 103 1986 1671 1677 (Pubitemid 17189022)
17. B. Carnemolla, A. Leprini, G. Allemanni, M. Saginati, and L. Zardi The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence J. Biol. Chem. 267 1992 24689 24692
18. B. Carnemolla, E. Balza, A. Siri, L. Zardi, M. Nicotra, A. Bigotti, and P. Natali A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors J. Cell Biol. 108 1989 1139 1148 (Pubitemid 19083757)
19. G. Mariani, A. Lasku, E. Balza, B. Gaggero, C. Motta, L. Di Luca, A. Dorcaratto, G.A. Viale, D. Neri D, and L. Zardi Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants Cancer 80 1997 2484 2489
20. G. Mariani, A. Lasku, A. Pau, G. Villa, C. Motta, G. Calcagno, G.Z. Taddei, P. Castellani, K. Syrigos, A. Dorcaratto, A.A. Epenetos, L. Zardi, and G.A. Viale A pilot pharmacokinetic and immunoscintigraphic study with the technetium-99m-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors Cancer 80 1997 2378 2384
21. M. Midulla, R. Verma, M. Pignatelli, M.A. Ritter, N.S. Courtenay-Luck, and A.J. George Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells Cancer Res. 60 2000 164 169 (Pubitemid 30058747)
22. E. Balza, F. Sassi, E. Ventura, A. Parodi, S. Fossati, W. Blalock, B. Carnemolla, P. Castellani, L. Zardi, and L. Borsi A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B Int. J. Cancer 125 2009 751 758
23. S. Bencharit, C.B. Cui, A Siddiqui, E.L. Howard-Williams, J. Sondek, K. Zuobi-Hasona, and I. Aukhil Structural insights into fibronectin type III domain-mediated signaling J. Mol. Biol. 367 2007 303 309 (Pubitemid 46295418)
24. T. Dietrich, T. Hucko, C. Schneemann, M. Neumann, A. Menrad, J. Willuda, K. Atrott, D. Stibenz, E. Fleck, K. Graf, and H.D. Menssen Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells Atherosclerosis 479 2011 359 364
25. E. Balza, L. Mortara, F. Sassi, S. Monteghirfo, B. Carnemolla, P. Castellani, D. Neri, R.S. Accolla, L. Zardi, and L. Borsi Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin Clin. Cancer Res. 12 2006 2575 2582
26. R. Verma, A.J.T. George, and N.S. Courtenay-Luck Generation of a single-chain Fv (sFv) against an oncofetal antigen associated with tumorigenesis and angiogenesis J. Int. Soc. Tumor Targeting 1 2009 9 21
27. J. Sambrook Molecular Cloning A Laboratory Manual third ed. 2001 Cold Spring Harbor Laboratory Press Cold Spring Harbor, New York
28. C.A. Kousparou, PhD Thesis, University of London, 2000.
29. P.A. Erba, M. Sollini, E. Orciuolo, C. Traino, M. Petrini, G. Paganelli, E. Bombardieri, C. Grana, L. Giovannoni, D. Neri, H.D. Menssen, and G. Mariani Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies J. Nucl. Med. 53 2012 922 927
30. M. Pedretti, A. Soltermann, S. Arni, W. Weder, D. Neri, and S. Hillinger Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer Lung cancer 64 2009 28 33
31. S. Sauer, P.A. Erba, M. Petrini, A. Menrad, L. Giovannoni, C. Grana, B. Hirsch, L. Zardi, G. Paganelli, G. Mariani, D. Neri, H. Dürkop, and H.D. Menssen Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients Blood 113 2009 2265 2274
32. D. Neri, and C.T. Supuran Interfering with pH regulation in tumours as a therapeutic strategy Nat. Rev. Drug Discov. 10 2011 767 777
33. S.I. Rudnick, and G.P. Adams Affinity and avidity in antibody-based tumor targeting Cancer Biotherapy Radiopharmaceuticals 24 2009 155 159
34. G.P. Adams, R. Schier, K. Marshall, E.J. Wolf, A.M. McCall, J.D. Marks, and L.M. Weiner Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies Cancer Res. 58 1998 485 490 (Pubitemid 28087411)
35. T.K. Eigentler, B. Weide, F. de Braud, G. Spitaleri, A. Romanini, A. Pflugfelder, R. González-Iglesias, A. Tasciotti, L. Giovannoni, K. Schwager, V. Lovato, M. Kaspar, E. Trachsel, H.D. Menssen, D. Neri, and C. Garbe A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma Clin. Cancer Res. 17 2011 7732 7742
36. J.F. Spicer, M.B. Jameson, P. Savage, D. Jodrell, S.M. Rudman, F. Erlandsson, G. Acton, and M. McKeage A phase I study of AS1409 a novel antibody-cytokine fusion protein in patients with malignant melanoma (MM) or renal cell carcinoma (RCC) J. Clin. Oncol. 27 2009 3024
37. P.D. Senter Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 13 2009 235 244